Fatal gene-editing trial in China sparks ethics and oversight concerns

A six-year-old girl in China died after receiving an experimental brain-directed CRISPR therapy, according to a report in Science. The tragedy has intensified calls for stronger ethical review and regulatory oversight of gene-editing trials.

The incident highlights gaps in patient protection and the need for transparent governance of emerging genome-editing technologies. Critics argue that current oversight mechanisms may be insufficient to prevent such outcomes.

The article also notes unrelated biotech news, including a narrow FDA panel vote that would allow compounding pharmacies to produce certain unregulated peptides, and a shortage of Sanofi's insulin pen, reflecting broader industry challenges.